SavedAdd your journal

Journals / Acta Orthopaedica et Traumatologica Turcica / 2015 / Cilt: 49 - Sayı: 1

Compliance, persistence, and preference outcomesof postmenopausal osteoporotic women receivinga flexible or fixed regimen of daily risedronate:A multicenter, prospective, parallel group study

AYDAN ORAL
Roman LORENC
Pages
67–74
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

At the final visit, 51% of patients in the flexible and 55% in the fixed regimen group considered the used risedronate regimen as excellent or very good (p=0.1440).Conclusion: A flexible dosing with daily risedronate appears be a valuable option in terms of compliance and persistence for patients with postmenopausal OP

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to examine the level of compliance and persistence in patients with postmenopausal osteoporosis (OP) receiving daily risedronate (5 mg) with either fixed dosing of three different timing regimens (A: before breakfast; B: in-between meals; C: before bedtime) or with flexible dosing and the effect on urinary N-terminal telopeptide of Type 1 collagen (NTX-1).
📊
Key Findings & Data:Methods: The study included 448 patients with postmenopausal OP.
💡
Conclusion & Impact:At the final visit, 51% of patients in the flexible and 55% in the fixed regimen group considered the used risedronate regimen as excellent or very good (p=0.1440).Conclusion: A flexible dosing with daily risedronate appears be a valuable option in terms of compliance and persistence for patients with postmenopausal OP
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study was to examine the level of compliance and persistence in patients with postmenopausal osteoporosis (OP) receiving daily risedronate (5 mg) with either fixed dosing of three different timing regimens (A: before breakfast; B: in-between meals; C: before bedtime) or with flexible dosing and the effect on urinary N-terminal telopeptide of Type 1 collagen (NTX-1). Methods: The study included 448 patients with postmenopausal OP. Patients were randomly assigned into six treatment groups each with a permutation of the treatment sequence (ABC, BCA, etc.) in the crossover phase (3x1 week) and randomized to 23 weeks of either the daily flexible (either regimen A, B or C) or fixed timing (only regimen A, B, or C) in the patient's preference phase. Urinary NTX-1 was tested.Results: A total of 433 patients participated in the patient's preference phase (49.7% preferred flexible and 50.3% fixed timing). There was no significant difference between the proportion of responders who were both compliant and persistent in the flexible (54.4%) and fixed regimens (53.7%) (p=0.8803). A significant difference between the flexible and fixed regimens was seen in persistence in favor of the flexible regimen (p=0.0306). There was no significant difference between the flexible and fixed regimens in terms of compliance (p=0.4611). Change in urinary NTX-1 did not show any difference between the two regimens. At the final visit, 51% of patients in the flexible and 55% in the fixed regimen group considered the used risedronate regimen as excellent or very good (p=0.1440).Conclusion: A flexible dosing with daily risedronate appears be a valuable option in terms of compliance and persistence for patients with postmenopausal OP

🔖

Cite This Article

ORAL, A., LORENC, R. (2015). Compliance, persistence, and preference outcomesof postmenopausal osteoporotic women receivinga flexible or fixed regimen of daily risedronate:A multicenter, prospective, parallel group study. Acta Orthopaedica et Traumatologica Turcica, Cilt: 49 - Sayı: 1, 67–74. https://ajindex.com/articles/216220

References (9)

  1. Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E. A meta-analysis of osteoporotic fracture risk with medica- tion nonadherence. Value Health 2011;14:571-81.
  2. Imaz I, Zegarra P, González-Enríquez J, Rubio B, Alcazar R, Amate JM. Poor bisphosphonate adherence for treat- ment of osteoporosis increases fracture risk: systematic re- view and meta-analysis. Osteoporos Int 2010;21:1943-51.
  3. Silverman SL, Schousboe JT, Gold DT. Oral bisphospho- nate compliance and persistence: a matter of choice? Osteo- poros Int 2011;22:21-6.
  4. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A sys- tematic review of persistence and compliance with bisphos- phonates for osteoporosis. Osteoporos Int 2007;18:1023- 31. International Osteoporosis Foundation. The adherence gap: Why osteoporosis patients don't continue with treatment; 2005 [cited 2011 October 17]. Available from: http:// www.iofbonehealth.org/publications/the-adherence-gap. html. Wells G, Cranney A, Peterson J, Boucher M, Shea B, Rob- inson V, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;1:CD004523. Jansen JP, Bergman GJ, Huels J, Olson M. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum 2011;40:275-84. e1-2. Reginster JY. Antifracture efficacy of currently avail- able therapies for postmenopausal osteoporosis. Drugs 2011;71:65-78.
  5. Gates BJ, Das S. Risedronate's Role in Reducing Hip Frac- ture in Postmenopausal Women with Established Osteo- porosis. Clin Med Insights Arthritis Musculoskelet Disord 2012;5:1-14.
  6. Zhong ZM, Chen JT. Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled tri- als. Clin Drug Investig 2009;29:349-57.
  7. Clemmesen B, Ravn P, Zegels B, Taquet AN, Christian- sen C, Reginster JY. A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporos Int 1997;7:488-95.
  8. Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnston CC Jr. Risedronate increases bone mass in an early postmenopaus- al population: two years of treatment plus one year of follow- up. J Clin Endocrinol Metab 1998;83:396-402.
  9. Hosking D, Adami S, Felsenberg D, Andia JC, Välimäki M, Benhamou L, et al. Comparison of change in bone re- sorption and bone mineral density with once-weekly alen- dronate and daily risedronate: a randomised, pl